Related Experiment Video

Updated: May 23, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Efficient siRNA targeted delivery into cancer cells by gastrin-releasing peptides

Mouldy Sioud1, Anne Mobergslien

  • 1Department of Immunology, Molecular Medicine Group, Institute for Cancer Research, Oslo University Hospital , Montebello, N-0310, Oslo, Norway.

Bioconjugate Chemistry
|March 27, 2012
PubMed

Insights

Gastrin-releasing peptides (GRPs) conjugated with small interfering RNAs (siRNAs) effectively target cancer cells expressing the GRP receptor. This peptide-siRNA delivery system shows promise for cancer RNA interference therapy by inhibiting survivin expression without inducing inflammation.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Oncology

Background:

  • Small interfering RNAs (siRNAs) offer therapeutic potential for cancer treatment.
  • Efficient and targeted delivery of siRNAs to cancer cells remains a significant challenge in RNA interference therapy.

Purpose of the Study:

  • To develop a targeted delivery system for siRNAs to cancer cells using peptide conjugation.
  • To investigate the efficacy of gastrin-releasing peptide (GRP)-siRNA conjugates for targeting GRP receptor-expressing cancer cells.

Main Methods:

  • Covalent conjugation of survivin-targeting siRNA with GRPs.
  • Assessment of cellular uptake of GRP-siRNA conjugates in MDA-MB 231 breast cancer cells.
  • Evaluation of survivin gene expression inhibition and inflammatory cytokine induction.

Main Results:

  • GRP-siRNA conjugates demonstrated specific uptake by GRP receptor-positive cancer cells, not normal cells or monocytes.
  • Uptake was dependent on GRP receptor expression, as confirmed by inhibition with excess free peptide.
  • Co-delivery using GRP and luteinizing hormone-releasing peptides enhanced uptake kinetics.
  • Peptide-siRNA conjugates effectively inhibited survivin expression and did not induce inflammatory responses.

Conclusions:

  • GRP receptor-mediated targeted delivery of siRNAs to cancer cells is feasible.
  • Peptide-siRNA conjugates represent a promising strategy for enhancing the efficacy of RNA interference cancer therapy.
  • This approach offers targeted delivery and therapeutic gene silencing with a favorable safety profile regarding inflammation.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...